34755047|t|Induction of Gut Microbial Tryptamine by SARS-CoV-2 in Nonhuman Primate Model Consistent with Tryptamine-Induced Model of Neurodegeneration.
34755047|a|The author discussed recently the possible molecular mechanisms that cause the COVID-19 disease symptoms. Here the analysis of the recent experimental data supports the hypothesis that production of the gut microbial tryptamine can be induced by the SARS-CoV-2 fecal viral activity due to the selective pressure or positive selection of tryptamine-producing microorganisms. In this report, the author suggests that the mechanism of microbial selection bases on the abilities of tryptamine to affect the viral nucleic acid. In other words, the gut microorganisms producing tryptamine are more resistant to SARS-CoV-2 fecal viral activity than microorganisms producing no tryptamine. Earlier we demonstrated the induction of neurodegeneration by tryptamine in human cells and mouse brain. Furthermore, we were able to uncover the human gut bacteria associated with Alzheimer's disease (AD) using PCR testing of human fecal samples with the new-designed primers targeting the tryptophan-tryptamine pathway. Likely, SARS-CoV-2 is one of the selective pressure factors in the cascade accelerating the neurodegenerative process in AD. This suggestion is consistent with a higher proportion of AD patients among COVID-19 related victims. Gut microbial tryptamine increase due to the viral infection-induced dysbiosis can synergize and potentiate the tryptamine cytotoxicity, necrotizing ability and other properties as a virulence factor.
34755047	27	37	Tryptamine	Chemical	MESH:C030820
34755047	41	51	SARS-CoV-2	Species	2697049
34755047	94	104	Tryptamine	Chemical	MESH:C030820
34755047	122	139	Neurodegeneration	Disease	MESH:D019636
34755047	220	236	COVID-19 disease	Disease	MESH:D000086382
34755047	358	368	tryptamine	Chemical	MESH:C030820
34755047	391	401	SARS-CoV-2	Species	2697049
34755047	478	488	tryptamine	Chemical	MESH:C030820
34755047	619	629	tryptamine	Chemical	MESH:C030820
34755047	713	723	tryptamine	Chemical	MESH:C030820
34755047	746	756	SARS-CoV-2	Species	2697049
34755047	811	821	tryptamine	Chemical	MESH:C030820
34755047	864	881	neurodegeneration	Disease	MESH:D019636
34755047	885	895	tryptamine	Chemical	MESH:C030820
34755047	899	904	human	Species	9606
34755047	915	920	mouse	Species	10090
34755047	969	974	human	Species	9606
34755047	1004	1023	Alzheimer's disease	Disease	MESH:D000544
34755047	1025	1027	AD	Disease	MESH:D000544
34755047	1050	1055	human	Species	9606
34755047	1114	1124	tryptophan	Chemical	MESH:D014364
34755047	1125	1135	tryptamine	Chemical	MESH:C030820
34755047	1153	1163	SARS-CoV-2	Species	2697049
34755047	1266	1268	AD	Disease	MESH:D000544
34755047	1328	1330	AD	Disease	MESH:D000544
34755047	1331	1339	patients	Species	9606
34755047	1346	1354	COVID-19	Disease	MESH:D000086382
34755047	1386	1396	tryptamine	Chemical	MESH:C030820
34755047	1417	1432	viral infection	Disease	MESH:D014777
34755047	1484	1494	tryptamine	Chemical	MESH:C030820
34755047	1495	1507	cytotoxicity	Disease	MESH:D064420
34755047	Association	MESH:C030820	MESH:D014364
34755047	Positive_Correlation	MESH:C030820	MESH:D000544
34755047	Positive_Correlation	MESH:C030820	MESH:D064420
34755047	Association	MESH:C030820	MESH:D014777
34755047	Positive_Correlation	MESH:C030820	MESH:D019636
34755047	Positive_Correlation	MESH:C030820	MESH:D000086382

